Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 29;14(1):197.
doi: 10.1186/s13195-022-01138-w.

Subjective cognitive decline is a better marker for future cognitive decline in females than in males

Affiliations

Subjective cognitive decline is a better marker for future cognitive decline in females than in males

Michael D Oliver et al. Alzheimers Res Ther. .

Abstract

Background: The identification of biomarkers for early detection of Alzheimer's disease (AD) is critical to the development of therapies and interventions targeted at symptom management and tracking the pathophysiology of disease. The endorsement of subjective cognitive decline (SCD) has emerged as a potential indicator of early change in cognitive status that may be predictive of future impairment at a time when measurable declines in neuropsychological performance cannot be detected. While there are numerous findings revealing sex differences in the prevalence of AD, there is a paucity of research examining sex differences in SCD. Therefore, the goal of this project was to determine if the relationship between the endorsement of SCD and future cognitive changes differ as a function of biological sex.

Methods: A sample of 3019 male and female healthy older adults (2188 without SCD, 831 with SCD), with a mean follow-up time of 5.7 years, were included from the Rush Alzheimer's Disease Center Research Sharing Hub. Linear regressions were performed to determine group differences in baseline cognitive scores, while linear mixed-effects models were completed to determine group differences in the rate of cognitive change over time.

Results: Individuals endorsing SCD had significantly lower baseline cognitive scores and increased rates of decline in all cognitive domains compared to those without SCD. Males exhibited significantly lower scores in baseline performance in global cognition, episodic memory, and perceptual speed regardless of SCD classification. Females with SCD were found to decline at significantly faster rates than both males with SCD and males and females without SCD in all cognitive domains over a maximum 15-year follow-up period.

Conclusions: SCD is related to lower baseline cognitive performance and faster cognitive decline compared to those who do not endorse SCD. Females with SCD have the fastest rate of decline suggesting that SCD may be more predictive of future decline in females than in males. Targeted assessments of SCD may allow for the identification of individuals for inclusion in intervention trials, and other research studies, aiming to attenuate casual disease processes, which may ultimately aid in the mitigation of sex disparities in AD.

Keywords: Alzheimer’s disease; Cognitive change; Sex disparities; Subjective cognitive decline.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Baseline cognitive differences in each domain for females and males with and without subjective cognitive decline. Top image represents baseline cognitive scores with mean and standard deviation for healthy older adults without subjective cognitive decline (SCD −). Bottom image represents baseline cognitive scores with mean and standard deviation for healthy older adults with subjective cognitive decline (SCD +)
Fig. 2
Fig. 2
Longitudinal cognitive change over time in females and males with and without subjective cognitive decline. SCD − , older adults without subjective cognitive decline. SCD + , older adults with subjective cognitive decline

Similar articles

Cited by

References

    1. Anderson RM, Hadjichrysanthou C, Evans S, Wong MM. Why do so many clinical trials of therapies for Alzheimer’s disease fail? Lancet. 2017;390(10110):2327–2329. doi: 10.1016/S0140-6736(17)32399-1. - DOI - PubMed
    1. Arvanitakis Z, Leurgans SE, Fleischman DA, Schneider JA, Rajan KB, Pruzin JJ, Shah RC, Evans DA, Barnes LL, Bennett DA. Memory complaints, dementia, and neuropathology in older blacks and whites. Ann Neurol. 2018;83(4):718–729. doi: 10.1002/ana.25189. - DOI - PMC - PubMed
    1. Ávila-Villanueva M, Fernández-Blázquez MA. Subjective cognitive decline as a preclinical marker for Alzheimer’s disease: the challenge of stability over time. Frontiers in aging neuroscience. 2017;9:377. doi: 10.3389/fnagi.2017.00377. - DOI - PMC - PubMed
    1. Barnes LL, Shah RC, Aggarwal NT, Bennett DA, Schneider JA. The Minority Aging Research Study: ongoing efforts to obtain brain donation in African Americans without dementia. Curr Alzheimer Res. 2012;9(6):734–745. doi: 10.2174/156720512801322627. - DOI - PMC - PubMed
    1. Barnes LL, Schneider JA, Boyle PA, Bienias JL, Bennett DA. Memory complaints are related to Alzheimer disease pathology in older persons. Neurology. 2006;67:1581–1585. doi: 10.1212/01.wnl.0000242734.16663.09. - DOI - PMC - PubMed

Publication types